Following on from the success of the initial round of BioExel programme applicants at NUI Galway in 2017-2108, the MedTech Accelerator programme is now accepting applications for the second cohort 2018-2019, with recruitment starting from July 20 to September 1, 2018.
Based at NUI Galway, BioExel offers €95,000 in seed funding to successful applicants along with six months of intensive training, mentoring, lab space and supported interactions with potential investors. The programme allows participants to build and commercially validate their technologies by working with existing entrepreneurial networks, mentors and management team.
BioExel is managed by medtech director Dr Sandra Ganly, also a co-founder of BioInnovate Ireland and senior research fellow at NUI Galway, and Fiona Neary, commercial director and co-founder of BioExel, and manager of the Business Innovation Centre at NUI Galway.
Fiona Neary said: “This first cohort of BioExel candidates have an array of innovations that have grown over the months at a rapid pace, de-risking their technologies and advancing in critical areas of medtech challenges. BioExel is key to transforming these opportunities as we deliver the next generation of investor ready, first class medical technologies to the marketplace.”
The first cohort of companies to complete the 2017-2018 BioExel programme joined a showcase and celebration of Ireland’s medtech ecosystem in Galway recently, attended by Minister for State Seán Kyne.
The six cohort of companies who have completed the BioExel programme 2017-2018:
1.) Bioprobe Diagnostics Ltd
Developing diagnostic products in a new regulated generation of water quality testing. Having spun out of NUI Galway in 2017, Bioprobe Diagnostics has developed a ground-breaking technology to quickly detect Legionella bacteria in water. The water-borne bacteria can lead to the life threatening form of pneumonia known as Legionnaires Disease. Bioprobe Diagnostics’ one-step test is five times faster and 30 per cent cheaper in direct costs than what is currently on the market. The company is currently raising funds and getting ready to launch their product in 2019.
2.) Bluedrop Medical Ltd
Predicting and preventing diabetic foot ulcers using computer vision, mapping associated complications and costs. Bluedrop Medical has developed a system for early Diabetic Foot Ulcers detection and patient compliance for health care systems. Daily temperature monitoring has been shown to prevent 70 per cent of ulcers in three randomised controlled trials. Bluedrop Medical has incorporated this technology into a novel home based device, and linked it up with an Artificial Intelligence (AI) remote monitoring system to provide actionable alerts to clinicians, enabling early intervention to prevent diabetic foot ulcers. Diabetic foot ulcers result in more than 150,000 amputations per year in Europe. Bluedrop Medical has developed a system that can prevent 70 per cent of them.
3.) Giant Leap Biotechnology Ltd
Designing a neuro regenerative product using cellular therapies and biomaterials delivery for spinal cord injury. GiantLeap Biotechnology is an Irish company focused on developing a veterinary therapy for spinal cord injury in canines which is estimated to be a $225 million annual market in the US. The technology has been created over a seven year research period by the founder Martin Codyre. GiantLeap Biotechnology is developing a biomaterial implant that will have protected intellectual property that combines with cells taken from the animal and implanted into the injured spinal cord.
4.) Hidramed Solutions Ltd
A wound care kit for effective management of chronic wounds, addressing patients’ unmet needs, providing comfort and adhesive free, secure dressing retention. Hidramed Solutions has developed a patentable two-part wound care kit that dramatically improves the wound care routine for patients. Of specific focus are individuals with Hidradenitis Suppurativa, (HS), a chronic debilitating skin disease. The condition is thought to be underdiagnosed and misdiagnosed, with a prevalence rate of one to four per cent of the general population. The locations of the lesions makes it difﬁcult for standard dressings to be worn comfortably and the options available are currently ineffective. Hidramed Solutions aim to transform the day-to-day comfort and quality of lives of suffers of Hidradenitis Suppurativa.
5.) Immunogrow Ltd
ImmunoGrow’s New Personalised Cancer Therapy aims to simplify production, thereby reducing costs and enhancing patient safety. Adoptive cell transfer is an anti-cancer approach that enhances the natural cancer-fighting ability of the body’s cells by removing immune system cells, growing and/or making changes to them outside of the body, and then re-infusing them back into the patient. ImmunoGrow aim to simplify production, reduce costs and enhance patient safety. Today, complex manufacturing processes limit the potential of cell-based cancer immunotherapies from the bespoke, operator intensive setting of the academic research lab to a commercially viable, good manufacturing practice-compliant environment. Innunogrow has mimicked in vivo (in the body of a living organism) growth conditions for T Cells (a subtype for white blood cells) by replicating the body’s natural growth conditions. This process improves output, reduces significant risk of invalid cell product, simplifies manufacturing requirement for skilled operator input and is easily integrated into automatic cell processing platforms.
6.) CompanionQMS Ltd
CompanionQMS is a cloud-enabled, secure, and scalable solution, delivering superior document management, intelligent workflows and reporting tools in one single interface. Developing QMS bespoke quality management software exclusively for medical device companies. Research has proven the need for an easy to implement and use, competitively priced QMS software. CompanionQMS is quality management software designed for medical device companies that provides a solution to this problem. CompanionQMS will enable companies to streamline product development and compliance while setting new standards for ease of use and ﬂexibility of design.
The western region already has a strong MedTech ecosystem and this is actively supported by the expertise and infrastructure at NUI Galway. The university is home to Ireland’s only centre for stem cell manufacturing, extensive translational and clinical facilities, biomedical sciences research laboratories, and the CÚRAM Centre for Research in Medical Devices. This is further strengthened by NUI Galway’s expertise in funding grants, knowledge transfer, and programmes such as BioInnovate and BioExel.
BioExel is a partnership programme funded by Enterprise Ireland, Western Development Commission, Galway University Foundation, Bank of Ireland seed and early stage equity fund, and hosted by NUI Galway.
To apply please contact the BioExel team for an application form at email@example.com
or phone 091 493150. For more information, visit: www.bioexel.ie